Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jul;59(7):764-9.
doi: 10.1136/jcp.2005.026435. Epub 2006 Mar 28.

Comparative genomic hybridisation in malignant deciduoid mesothelioma

A Scattone  1 , A Pennella, M Gentile, M Musti, P Nazzaro, A L Buonadonna, A Marzullo, D Cavone, L Pollice, G Serio
Affiliations

Comparative genomic hybridisation in malignant deciduoid mesothelioma

A Scattone et al. J Clin Pathol. 2006 Jul.

Abstract

Background: Malignant deciduoid mesothelioma is a rare variant of epithelioid mesothelioma. This tumour generally has poor prognosis, and can be asbestos related.

Aim: To identify peculiar genetic changes responsible for critical phases in pathogenesis of malignant deciduoid mesothelioma and their prognostic relevance.

Methods: Comparative genomic hybridisation was carried out in six cases of malignant pleural deciduoid mesothelioma, four sporadic and two familial. All cases were found to be asbestos related. Four patients died during follow-up and the mean survival was 29.5 (SD 14.2, range 12-43) months.

Results: Genetic abnormalities were found in all the tumour tissues, the most frequent being chromosomal gains at 1p, 12q, 17, 8q, 19 and 20 and losses at 13q, 6q and 9p. Survival was found to be longer in those patients who presented a smaller number of losses (< or =2) in the tumorous chromosomes.

Conclusions: Although numerous genetic changes are presented by deciduoid mesotheliomas, certain chromosomal regions are preferentially affected. The clinical outcome for this mesothelioma subtype is predicted by the number of losses.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Battifora H, McCaughey W T E. Tumours and pseudotumours of the serosal membranes. 3rd series. In: Rosai J, Sobin IH, eds. Atlas of tumour pathology. Washington, DC: Armed Forces Institute of Pathology, 199515–88.
    1. Sterman D H, Kaiser L R, Albelda S M. Advances in the treatment of malignant pleural mesothelioma. Chest 1999116504–520. - PubMed
    1. Curran D, Sahmoud T, Therasse P.et al Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 199816145–152. - PubMed
    1. Edwards J G, Abrams K R, Leverment J N.et al Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 200055731–735. - PMC - PubMed
    1. Travis W D, Colby T V, Corrin B.et al Histological typing of lung and pleural tumours. In: Sobin LH, pathologists from 14 countries, eds. International histological classification of tumours. 3rd edn. Geneva: World Health Organization, 199951–54.

MeSH terms